PMID- 12927309
OWN - NLM
STAT- MEDLINE
DCOM- 20031110
LR  - 20191210
IS  - 0166-3542 (Print)
IS  - 0166-3542 (Linking)
VI  - 59
IP  - 3
DP  - 2003 Aug
TI  - HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by 
      electroretinography, a non-invasive technique.
PG  - 193-200
AB  - The purpose of these studies was to investigate the use of non-invasive 
      electroretinography for the evaluation of retinal disease and its treatment in an 
      ocular murine cytomegalovirus (MCMV) disease model. While under anesthesia, 
      10(2.6)plaque forming units (pfu) of salivary gland passaged, Smith strain MCMV 
      was injected in the anterior chamber of 6- to 8-week-old severe combined 
      immunodeficiency (SCID) mice. At various times post-inoculation, bright-flash 
      scotopic electroretinogram, viral titer, and histology were obtained from the 
      injected eye. Antiviral therapy was tested using 0.1 and 5mg/kg/day subcutaneous 
      injections of HPMPC (Cidofovir) once daily for 5 consecutive days. In infected 
      animals, the a- and b-waves of the electroretinographic (ERG) signal were 
      significantly reduced as of 10 days post-inoculation when compared to control 
      animals. Therapy with HPMPC 0.1mg/kg/day subcutaneously (s.c.) once daily for 5 
      consecutive days was able to delay the decrease in ERG wave amplitude and inhibit 
      viral replication, whereas 5mg/kg/day s.c. significantly protected the ERG, 
      completely inhibited viral replication, and maintained ocular viral titer below 
      the limit of detection for up to 17 days post-infection. The reduction of ERG 
      activity during progression of retinal disease correlated well with reduction of 
      disease pathology. ERG recording represents a valuable non-invasive technique to 
      measure the progression of the retinal disease induced by MCMV and the efficacy 
      of antiviral treatment in the ocular MCMV disease model.
FAU - Garneau, Michel
AU  - Garneau M
AD  - Boehringer Ingelheim (Canada) Ltd Research and Development, 2100 Cunard Street, 
      Laval,Quebec, Canada H7S 2G5. mgaeneau@lav.boehringer-ingellheim.com
FAU - Bolger, Gordon T
AU  - Bolger GT
FAU - Bousquet, Christiane
AU  - Bousquet C
FAU - Kibler, Philip
AU  - Kibler P
FAU - Tremblay, Francois
AU  - Tremblay F
FAU - Cordingley, Michael G
AU  - Cordingley MG
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Antiviral Agents)
RN  - 0 (Organophosphonates)
RN  - 0 (Organophosphorus Compounds)
RN  - 8J337D1HZY (Cytosine)
RN  - JIL713Q00N (Cidofovir)
SB  - IM
MH  - Animals
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - Cidofovir
MH  - Cytomegalovirus Retinitis/*drug therapy/virology
MH  - Cytosine/administration & dosage/*analogs & derivatives/*therapeutic use
MH  - Disease Models, Animal
MH  - Electroretinography/methods
MH  - Eye Infections, Viral/drug therapy/virology
MH  - Female
MH  - Herpesviridae Infections/drug therapy/virology
MH  - Humans
MH  - Mice
MH  - Mice, SCID
MH  - Muromegalovirus/*pathogenicity
MH  - *Organophosphonates
MH  - Organophosphorus Compounds/administration & dosage/*therapeutic use
MH  - Retina/virology
MH  - Treatment Outcome
MH  - Virus Replication
EDAT- 2003/08/21 05:00
MHDA- 2003/11/11 05:00
CRDT- 2003/08/21 05:00
PHST- 2003/08/21 05:00 [pubmed]
PHST- 2003/11/11 05:00 [medline]
PHST- 2003/08/21 05:00 [entrez]
AID - S0166354203001128 [pii]
AID - 10.1016/s0166-3542(03)00112-8 [doi]
PST - ppublish
SO  - Antiviral Res. 2003 Aug;59(3):193-200. doi: 10.1016/s0166-3542(03)00112-8.